BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 24313958)

  • 21. Success of rechallenging dabrafenib and trametinib combination therapy after trametinib-induced rhabdomyolysis: a case report.
    Muto Y; Ng W; Namikawa K; Takahashi A; Tsutsumida A; Nishida M; Yamazaki N
    Melanoma Res; 2018 Apr; 28(2):151-154. PubMed ID: 29356791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor.
    Galliker NA; Murer C; Kamarashev J; Dummer R; Goldinger SM
    Eur J Dermatol; 2015 Apr; 25(2):177-80. PubMed ID: 25788221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Development of serous retinopathy during therapy of a metastatic cutaneous melanoma].
    Lüdeke I; Terheyden P; Grisanti S; Lüke M
    Ophthalmologe; 2016 Oct; 113(10):861-863. PubMed ID: 26873702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab.
    Minor DR; Puzanov I; Callahan MK; Hug BA; Hoos A
    Pigment Cell Melanoma Res; 2015 Sep; 28(5):611-2. PubMed ID: 25996827
    [No Abstract]   [Full Text] [Related]  

  • 25. Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations.
    Spain L; Julve M; Larkin J
    Expert Opin Pharmacother; 2016; 17(7):1031-8. PubMed ID: 27027150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma.
    Park JJ; Hawryluk EB; Tahan SR; Flaherty K; Kim CC
    JAMA Dermatol; 2014 Mar; 150(3):307-11. PubMed ID: 24352115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.
    Schadendorf D; Amonkar MM; Stroyakovskiy D; Levchenko E; Gogas H; de Braud F; Grob JJ; Bondarenko I; Garbe C; Lebbe C; Larkin J; Chiarion-Sileni V; Millward M; Arance A; Mandalà M; Flaherty KT; Nathan P; Ribas A; Robert C; Casey M; DeMarini DJ; Irani JG; Aktan G; Long GV
    Eur J Cancer; 2015 May; 51(7):833-40. PubMed ID: 25794603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Facing the challenges of new melanoma-targeted therapies: Treatment of severe fevers associated with dabrafenib/trametinib combination therapy.
    Lindsay JN; Barras M
    J Oncol Pharm Pract; 2015 Aug; 21(4):293-5. PubMed ID: 24664475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma.
    Knispel S; Zimmer L; Kanaki T; Ugurel S; Schadendorf D; Livingstone E
    Expert Opin Drug Saf; 2018 Jan; 17(1):73-87. PubMed ID: 29050517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.
    Daud A; Gill J; Kamra S; Chen L; Ahuja A
    J Hematol Oncol; 2017 Jan; 10(1):3. PubMed ID: 28052762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiac tamponade induced by dabrafenib and trametinib combination therapy for melanoma: Case report.
    Sundaram VR; Abbas T
    Medicine (Baltimore); 2018 Nov; 97(44):e12751. PubMed ID: 30383630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
    Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM
    N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II).
    Atkinson V; Sandhu S; Hospers G; Long GV; Aglietta M; Ferrucci PF; Tulyte S; Cappellini GCA; Soriano V; Ali S; Poprach A; Cesas A; Rodriguez-Abreu D; Lau M; de Jong E; Legenne P; Stein D; King B; van Thienen JV
    Melanoma Res; 2020 Jun; 30(3):261-267. PubMed ID: 31895752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apparent darkening of scalp hair related to pili multigemini Following dabrafenib and trametinib.
    Avila C; Hoffman K; Milani-Nejad N; Pootrakul L
    Dermatol Online J; 2020 Jan; 26(1):. PubMed ID: 32155032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world efficacy and safety data for dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced melanoma.
    Takahashi A; Namikawa K; Nakano E; Yamazaki N
    J Dermatol; 2020 Mar; 47(3):257-264. PubMed ID: 31876308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting.
    Matter-Walstra K; Braun R; Kolb C; Ademi Z; Dummer R; Pestalozzi BC; Schwenkglenks M
    Br J Dermatol; 2015 Dec; 173(6):1462-70. PubMed ID: 26332527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial.
    Algazi AP; Othus M; Daud AI; Lo RS; Mehnert JM; Truong TG; Conry R; Kendra K; Doolittle GC; Clark JI; Messino MJ; Moore DF; Lao C; Faller BA; Govindarajan R; Harker-Murray A; Dreisbach L; Moon J; Grossmann KF; Ribas A
    Nat Med; 2020 Oct; 26(10):1564-1568. PubMed ID: 33020646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.
    Long GV; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Grob JJ; Chiarion-Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JB; Hansson J; Utikal J; Ferraresi V; Kovalenko N; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; DeMarini DJ; Irani JG; Swann S; Legos JJ; Jin F; Mookerjee B; Flaherty K
    Lancet; 2015 Aug; 386(9992):444-51. PubMed ID: 26037941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
    Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pyoderma Gangrenosum Under Dabrafenib and Trametinib for Metastatic Melanoma.
    Saint-Jean M; Le Moigne M; Daguze J; Bossard C; Peuvrel L; Quéreux G; Dréno B
    Acta Derm Venereol; 2018 Apr; 98(5):530-531. PubMed ID: 29362816
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.